报价延迟最少15分钟:2026/04/28 03:13 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
81.76 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.14/--
|
|
企业价值
4.00B
|
| 资产负债 |
|
每股账面净值
10.44
|
| 现金流量 |
|
现金流量率
0.01
|
| 损益表 |
|
收益
305.11M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates(QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response. |
